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Abstract Downstream A3 receptor signalling plays an
important role in the regulation of cell death and prolifer-
ation. Therefore, it is important to determine the molecular
pathways involved through A3 receptor stimulation. The
phosphatidylinositide-3-OH kinase (PI3K)/Akt and the Raf/
mitogen-activated protein kinase (MAPK/ERK) kinase
(MEK)/mitogen-activated protein kinase (MAPK) path-
ways have central roles in the regulation of cell survival
and proliferation. The crosstalk between these two path-
ways has also been investigated. The focus of this review
centres on downstream mediators of A3 adenosine receptor
signalling.
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Abbreviations
CHO-hA3 CHO cells transfected with the human
recombinant A3
Cl-IB-
MECA
N>
>6(3-iodobenzyl)2-chloroadenosine-50-N-
methyluronamide
DPCPX 1,3-dipropyl-8-cyclopentylxanthine
ERK extracellular signal-regulated kinase
GSK-3β glycogen synthase kinase
IB-MECA N>
6-(3-iodobenzyl)adenosine-50-N-
methyluronamide
MAPK mitogen-activated protein kinase
MEK mitogen-activated protein kinase kinase
MRE
3008F20
5N-(4-methxyphenyl-carbomoyl)amino-8-
propyl-2-(2-furyl)-pyrazolo-[4,3e]1,2,3-tria-
zolo [1,5c] pyrimidine
MRE
2029F20
[N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-
1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-
yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide]
NECA 50-N(ethyl)carboxamidoadenosine
pAkt phosphorylated Akt
PI3K phosphatidylinositol 3-kinase
PLC phospholipase C
PKA protein kinase A
SCH
58261
7-(2-phenylethyl)2-(2-furyl)pyrazolo[4,3e]
1,2,3-triazolo[1,5c]pyrimidine
siRNA small interfering RNA
siRNAA3 small interfering RNA that targets A3
receptor mRNA
Overview of the A3 receptor signalling
A3 adenosine receptors couple, via G proteins, to classical
second-messenger pathways such as inhibition of adenylyl
cyclase [1], stimulation of phospholipase C (PLC) [2] and
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controls important biological events, such as cell survival [4].
In particular, the A3 receptor-mediated induction of apoptosis
or protection from cell death has been demonstrated in
various experimental models and systems [4]. Certainly, A3
receptors have an important role in the control of neuronal
cell death [5, 6]. Neuroprotective activity has been demon-
strated following chronic administration of the A3 receptor
agonist N
6-(3-iodobenzyl)adenosine-50-N-methyluronamide
,
(IB-MECA) to gerbils with cerebral ischaemia, thus support-
ing speculation that treatment with adenosine A3 receptor
agonists may decrease the infarct size following focal brain
ischaemia [7]. A3 receptors have also been involved in
cardioprotection during prolonged stimulated ischaemia by
rescuing injured myocytes [8]. Activation of A3 adenosine
receptor protects against doxorubicin-induced cardiotoxicity
and can attenuate myocyte injury during hypoxia [9–12].
Furthermore, A3 adenosine receptor activation triggers
phosphorylation of protein kinase B and protects rat
basophilic leukemia 2H3 mast cells from apoptosis [13]. In
human melanoma cells, A3 adenosine receptor triggers a pro-
survival signal, and the blockade of A3 receptors by selective
antagonists induces deleterious consequences [14].
In contrast, high concentrations of the agonists for A3
receptor can induce apoptosis. Different studies have
suggested the involvement of the A3 receptor in adeno-
sine-induced apoptosis using N
6(3-iodobenzyl)2-chloro-
adenosine-50N-methyluronamide (Cl-IB-MECA) in rat
astrocytes [15] and human astrocytoma ADF cells [16],
human peripheral blood mononuclear cells, both myeloid
and lymphoid cells (U937, HL60) [17, 18] and cardiac
myocytes [19, 20]. However, further investigations on CHO
cells transfected with the human recombinant A3 adenosine
receptors (CHO-hA3) and on mast and lymphoma cell lines
[13, 21–23] revealed no involvement of A3 receptors on
induction of cell death, suggesting that the A3 receptor
signalling is highly dependent on the cell-specific or tissue-
specific context.
The molecular pathways sustaining the action of A3
receptor on cell survival have been defined. The present
review will focus on the Akt-mediated signalling and the
mitogen-activated protein (MAP) kinase cascades as prin-
cipal pathways regulated by the A3 receptor.
The A3 receptor and the Ras-Raf-MEK-ERK signal
transduction cascade
The A3 receptor signalling cascade has been demonstrated
in different cellular models. Firstly, it has been suggested
that A3 receptor modulates mitogenesis and the activation
of ERK1/2 in human foetal astrocytes [24]. Physiological
concentrations of adenosine (10–100 nM) have been
demonstrated to cause an increase in phosphorylation of
ERK1/2 after 5 min in CHO cells transfected with any one
of the four adenosine receptors [25]. Levels of adenosine
reached duringischaemia(3μM)induce amore pronounced,
but still transient, activation of ERK1/2. Thus, all the human
adenosine receptors transfected into CHO cells are able to
activate ERK1/2 at physiologically relevant concentrations
of the endogenous agonist. Both 50-N(ethyl)carboxamido-
adenosine (NECA) and the endogenous agonist (adenosine)
lead to a time- and dose-dependent increase in ERK1/2
phosphorylation, at concentrations as low as 10 nM to
30 nM [25]. Moreover, these studies show that A3 receptor
signalling in CHO-hA3 cells leads to stimulation of ERK1/2
activity. In particular, A3 receptor signalling to ERK1/2
depends on βγ release from PTX-sensitive G proteins,
PI3K, Ras and MEK [26]. Functional A3 receptors acti-
vating ERK1/2 have also been described in microglia cells
[27]. In this cell model, by selectively stimulating the A3
receptor in both primary mouse microglia cells and in the
N13 microglia cell line with the agonist Cl-IB-MECA, it
has been found to be a biphasic, partly Gi protein-depen-
dent influence on the phosphorylation of the ERK1/2.
However, different results have been obtained on this
issue. In the human melanoma A375 cell line it has been
demonstrated that Cl-IB-MECAwas unable to activate ERK
phosphorylation, while the A3 antagonists are able to
improve the activity of MEKs [14]. Similar results were
obtained in murine melanoma cells [28]. Furthermore, re-
cently, we have found that A3 adenosine receptor stimula-
tion inhibits cell proliferation by impairment of ERK kinase
activation [29]. We studied the changes in ERK1/2
phosphorylation after treatment of melanoma cells with
Cl-IB-MECA 10 μM in a time-course experiment. Inter-
estingly, prolonged inhibition of ERK1/2 phosphorylation
was induced after the treatment of melanoma cells with Cl-
IB-MECA, and this effect was sustained for 2 h after Cl-IB-
MECA treatment. The kinetics of ERK1/2 phosphorylation
reduction was very rapid: Cl-IB-MECA appeared to impair
ERK1/2 phosphorylation after 5 min. Furthermore, we
investigated the dose-dependence of Cl-IB-MECA to
inhibit ERK1/2 phosphorylation. We found that the
inhibition of ERK1/2 phosphorylation was produced by
Cl-IB-MECA with an EC50 of 4.3 ± 0.5 μM and 2.2 ±
0.3 μM for ERK-2 and ERK-1, respectively. The effect of
Cl-IB-MECA was mediated by A3 receptor because, while
the A1,A 2A and A2B receptor antagonists were not able to
prevent ERK1/2 inhibition induced by Cl-IB-MECA, the
selective A3 receptor antagonist MRE 3008F20 (0.1 μM)
abrogated the Cl-IB-MECA-induced inhibition of ERK1/2
activation. Furthermore, we found that the inhibition of A3
receptor expression is sufficient to block Cl-IB-MECA-
induced inhibition of ERK1/2 phosphorylation levels.
These results emphasize the role of A3 receptors as
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tion between A3 receptor stimulation and MEK/MAPK
signalling in melanoma cells.
To explain why different results have been obtained on
this issue it could be suggested that this mechanism may be
peculiar for melanoma cells, having a misregulation of
proliferative pathways, as A3 receptors increased ERK1/2
phosphorylation in CHO-hA3 cells in a dose-dependent
manner [26] and induced a biphasic effect on the
phosphorylation levels of ERK1/2 on microglia cells [27].
Further studies in other different cell systems will enhance
our understanding of the role of A3 receptors in the
modulation of mitogenic signalling.
Furthermore, it has been shown that MAPK activation is
involvedinA3 receptor regulation, both contributing to direct
phosphorylation and controlling G protein-coupled receptor
(GPCR) kinase protein membrane translocation, which are
involved in receptor phosphorylation. Thus, an active MAPK
pathway appears to be essential for A3 receptor phosphory-
lation, desensitization and internalization [30].
The A3 receptor and the Akt signal
transduction cascade
Another importantpathway thatistriggeredbyadenosinevia
A3 receptor is the PI3K/Akt pathway [4]. One of the crucial
downstream targets of PI3K is the serine/threonine kinase
Akt. Active Akt causes a variety of biological effects,
including suppression of apoptosis by phosphorylation and
inactivation of several targets along pro-apoptotic pathways
[31]. In particular, activated Akt is able to phosphorylate a
variety of downstream substrates, e.g., the pro-apoptotic
molecule Bad, caspase-9, the forkhead family transcription
factors, I-K (a kinase that regulates the NF-kB transcription
factor) and Raf.
Recent studies have demonstrated that protein kinase A
(PKA) and PKB/Akt phosphorylate and inactivate glycogen
synthase kinase 3β (GSK-3β), a serine/threonine kinase
acting as a key element in the Wnt signalling pathway. In
its active form, GSK-3β suppresses mammalian cell
proliferation [28]. Only one study has indicated that the
A3 agonist IB-MECA is able to decrease the levels of PKA,
a downstream effector of cAMP, and of the phosphorylated
form of PKB/Akt in melanoma cells. This implies the
deregulation of the Wnt signalling pathway, generally
active during embryogenesis and tumorigenesis to increase
cell cycle progression and cell proliferation [28]. In
contrast, several studies have indicated the ability of A3
receptor to activate Akt [4]. There is evidence that A3
adenosine receptor activation triggers phosphorylation of
PKB/Akt, protecting rat basophilic leukemia 2H3 mast cells
from apoptosis by a pathway involving the βγ subunits of
Gi and PI3K-β. This process is blocked by pertussis toxin
and wortmannin [13]. More recently, it has been demon-
strated that A3 receptors trigger increases in Akt phosphor-
ylation in rat cardiomyocytes via a Gi/Go-protein and
tyrosine kinase-dependent pathway [32]. An elegant study
has recently documented a role of adenosine A3 receptor in
cell survival signalling in resveratrol preconditioning of the
heart. This study provides evidence that resveratrol pre-
conditions the heart through the activation of adenosine A1
and A3 receptors, transmitting a survival signal through the
PI3-kinase-Akt-Bcl2 signalling pathway [33]. Further stud-
ies indicate that A3 receptor activation can decrease IL-12
production, which is also mediated by interfering with
PKB/Akt [34, 35]. Using human melanoma A375 cells we
showed that A3 adenosine receptor stimulation results in
PI3K-dependent phosphorylation of Akt. We found that
serum-deprived A375 melanoma cells had no basal Akt
phosphorylation, whereas the A3 receptor agonist Cl-IB-
MECA treatment resulted in the phosphorylation of Akt at
the Ser 573 phosphorylation site. In particular, we have
demonstrated that the antiproliferative effect of Cl-IB-MECA
is mediated by a PLC-PI3K-Akt signalling pathway [29].
Crosstalk between MAPK and PI3K/Akt signalling
pathways, and modulation by the A3 receptor
Crosstalk between the PI3K and the Raf/MEK/ERK path-
ways has been reported on multiple levels, with some
research stating that PI3K activity is essential for induction
of Raf/MEK/ERK activity [31, 36]. Additional studies
suggest that the PI3K pathway enhances and/or synergizes
with Raf/MEK/ERK signalling to provide a more robust
signal through the lower components of the MAPK cascade
(i.e., ERK). However, there is conflicting evidence that
states that Akt is able to phosphorylate Raf, thereby
efficiently abrogating Raf activity on downstream sub-
strates [37–41].
Considering the pleiotropic substrates and the ubiquitous
expression of ERK, cell specific regulation must occur to
ensure conduction of the appropriate signal.
Recently, we investigated the role of the adenosinergic
system in the regulation of ERK activation in melanoma
cells. We focused our attention on melanoma cells because
the importance has been demonstrated of small autacoids,
primarily thought to be neurotransmitters, in mediating a
variety of biological activities in the skin [14, 42–45]. In
particular, several studies have indicated that adenosine, via
stimulation of its receptors, is involved in cell proliferation
and cell death. In agreement with these studies, we also
found that A3 receptor inhibits human melanoma A375 cell
line proliferation [42].
The activities of Akt or MAPK, or both, are elevated in
many cancer cells and are known to play critically
important roles in cellular proliferation [31, 36, 46]. On
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A3 receptor stimulation regulates cell growth signalling via
the ERK1/2 and/or the Akt pathway in melanoma cells.
We found that Akt phosphorylation mediated by Cl-IB-
MECA induced Raf phosphorylation at an inhibitory
phosphorylation site on Ser 259 of Raf. As a consequence,
Cl-IB-MECA inactivated Raf in a dose- and time-depen-
dent manner. Interestingly, Cl-IB-MECA stimulation
resulted in a time- and dose-dependent reduction in
ERK1/2 phosphorylation.
We examined whether any crosstalk existed between
ERK1/2 and Akt pathways in A375 melanoma cells. The
classical MAPK cascade leads from the Ras kinases to the
MAPKK MEK1/2. There is evidence that Akt is able to
phosphorylate Raf, thereby efficiently abrogating Raf
activity on downstream substrates [39, 41, 47]. We studied
the effects of A3 receptor stimulation on the proliferation of
melanoma cells in the presence of specific inhibitors of the
PI3K and Akt signal transduction pathways. We could
effectively block the Cl-IB-MECA-induced reduction of
ERK1/2 phosphorylation with an inhibitor of PI3K. Indeed,
application of Cl-IB-MECA in combination with PI3K
inhibition resulted in a clear increase of ERK1/2 phosphor-
ylation when compared with P-ERK1/2 in the presence of
Cl-IB-MECA alone. These data suggest that the Ras-Raf-
MEK-ERK pathway is normally activated by A3 receptor
stimulation, as is the PI3K-Akt route. It is clear that these
apparently separate routes should actually interact.
In order to investigate the functionality of A3 receptors
expressed in melanoma cells we used the selective
adenosine analogue Cl-IB-MECA. It is not clear whether
the growth inhibitory action of micromolar concentrations
of the A3 receptor agonist Cl-IB-MECA is due to its role
as an extracellular ligand for cell surface receptors or
whether it acts intracellularly as a second messenger. In
addition, this agonist may, in high concentrations,
activate A1 receptors, which, however, when compared
with A3 receptors, are expressed at low level in A375 cells
(BMAX = 23 ± 7 fmol mg
−1 of protein and BMAX = 291 ±
50 fmol mg
−1 of protein for A1 and A3, respectively) [48].
Thus, the effects we report here on melanoma cell
proliferation and on ERK1/2 phosphorylation induced by
Cl-IB-MECA using high (10
−6 M) concentrations of Cl-IB-
MECA are almost certainly due to A3 receptor stimulation.
In particular, the effects of Cl-IB-MECA on cell prolifer-
ation and on ERK1/2 phosphorylation are not mediated by
A1,A 2A or A2B receptors. In support of this conclusion,
DPCPX, SCH 58261 and MRE 2029F20, adenosine
receptor antagonists highly selective for A1,A 2A and A2B
receptors [49, 50], respectively, did not block the inhibitory
effect of A3 receptor stimulation on cell proliferation and on
P-ERK1/2 modulation. On the contrary, the effects on cell
proliferation and on P-ERK1/2 modulation were inhibited
by the A3 receptor antagonist, MRE 3008F20. Furthermore,
the Cl-IB-MECA-induced effects on cell proliferation and
ERK1/2 phosphorylation in human A375 melanoma cells
were abolished in cells in which A3 receptor protein was
knocked down by si-RNAA3 treatment, when compared
with wild-type cells. These findings, together with the
specificity of the agonist used, makes us confident that the
effects are due to the A3 receptor subtype.
A3 receptor stimulation inhibits the proliferation of
melanoma cells partly by a PLC-sensitive mechanism.
Pretreatment of cells with a PLC-γ inhibitor strongly
abrogated the Cl-IB-MECA effect on cell proliferation
and on ERK1/2 phosphorylation, suggesting a critical role
for PLC-γ in A3 receptor signalling. Furthermore, pretreat-
ment of A375 cells with a PI3K inhibitor and an Akt
inhibitor impaired Cl-IB-MECA-induced inhibition of cell
proliferation and the effects of A3 receptor stimulation on
Raf, MEK1/2 and ERK1/2 phosphorylation. These data
suggest that the A3 adenosine receptor signals through a
pathway that includes PI3K-Akt. In contrast, Ras was not
activated. These results confirm that, in A375 cells, A3
receptors decrease MEK1/2-ERK1/2 phosphorylation and
cell proliferation via the inhibition of Raf by a PI3K-Akt
pathway, without affecting Ras.
Our results indicate that Cl-IB-MECA acts extracellular-
ly as a first messenger for cell surface receptors. In A375
cells the inhibition of PLC-PI3K-Akt signalling is able to
block the effect of A3 receptor stimulation on cell
proliferation, suggesting that, in the melanoma cell system,
an inhibitory connection between PLC-PI3K-Akt and
ERK1/2 is present (Figure 1).
Finally, we have described the molecular mechanism
sustained by Cl-IB-MECA interfering with cell prolifera-
PI3K
Akt
RAS
MEK1/2
Erk1/2
Raf
A3
Extracellular mitogenic 
factors
Adenosine
Cell proliferation 
induction
Figure 1 A3 adenosine receptor stimulates PI3K-dependent phos-
phorylation of Akt, leading to the reduction of basal levels of ERK1/2
phosphorylation that, in turn, inhibits cell proliferation
630 Purinergic Signalling (2006) 2:627–632tion. Cl-IB-MECA, via A3 adenosine receptor binding,
activates PLC-PI3K-Akt signalling that, in turn, reduces P-
ERK1/2 levels necessary for cell proliferation. As a
consequence, cells accumulate in G0/G1 cell cycle phases,
and low level of DNA incorporation is observed.
Further definition of the pathways leading to ERK1/2
inactivation, and translation into an in vivo model, are
required to clarify whether adenosine signalling in vivo has
characteristics similar to those observed in this in vitro
model. In this scenario the regulation of ERK1/2 by A3
receptor and PI3K would represent an important aspect of
adenosine signalling.
Although it is possible that the signalling pathways may
be different in other cellular backgrounds, it seems likely
that the biological events regulated by adenosine A3
receptors under physiological and pathophysiological con-
ditions may depend not only on changes in cAMP and Ca
2+
but also on mitogenic signalling via ERK1/2 and Akt.
Conclusions
Work by several groups, including ours, has shown a
modulation of the Akt/Ras/Raf/MEK/ERK signalling path-
way by adenosine. We propose that this modulation is
essential to determine the final physiological response of A3
adenosine receptor activation.
Of great interest are the different effects of adenosine on
the Akt/Ras/Raf/MEK/ERK signalling pathway modulation
in different cells.
Interestingly, adenosine may be, on the one hand,
preventing the proliferative activation of ERK1/2 by block-
ing Raf through Akt activation and, on the other hand,
stimulating PI3K activation in order to induce cell survival.
We believe that the opposite effects of adenosine are due to
the presence of more than one receptor subtype in the same
cellular system, each mediating seemingly opposite actions,
e.g., having conflicting actions on cell proliferation and cell
death. As a consequence, the net effect may not be defined. It
is clear that adenosine concentration may determine the
pattern of differential activation of co-expressed receptor
subtypes. One adenosine receptor may also be coupled to
more than one G protein. Several studies are helping to show
if such coupling is physiologically important [51].
Further work to determine the various physiological
responses mediated by A3 receptor stimulation through the
regulation of the Akt/Ras/Raf/MEK/ERK pathway will help
us to understand the role played by adenosine in cell
proliferation and cell death.
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